← Leaderboards
Iliya Lefterov
University Of Pittsburgh At Pittsburgh
$9,615,606
Attributed
$18,593,869
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,593,869 · 12
By mechanism
R01$11,034,832 · 4
RF1$6,013,456 · 2
R21$820,640 · 2
R56$440,615 · 1
R03$239,326 · 2
R13$45,000 · 1
Top collaborators
- Radosveta P Koldamova19 shared
- Jonathan Schug6 shared
- Aaron Barchowsky2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Radosveta P Koldamova$12,908,953
- Robert D Nicholls$6,020,455
- Leaf Huang$16,174,553
- Fadi G. Lakkis$19,632,585
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseasePathogenesisBrainMolecularEpigenetic ProcessGenesMediatingPhenotypeLate Onset Alzheimer DiseaseImpaired CognitionAffectCholesterolDementiaNeuronsGenotypeBaseDepositionGenetic TranscriptionPathologyAmyloidNuclearPreventGenome-Wide
Grant awards (34)
ncRNAs in plasma EVs of AD patients and their discriminatory power as biomarkers$1,437,361
RF1 · FY2025 · AG · contact PI
The interplay between Tau and ncRNAs â genomic and epigenomic clues to early AD pathogenesis$691,227
R01 · FY2025 · AG
The interplay between Tau and ncRNAs â genomic and epigenomic clues to early AD pathogenesis$718,053
R01 · FY2024 · AG
The interplay between Tau and ncRNAs â genomic and epigenomic clues to early AD pathogenesis$729,819
R01 · FY2023 · AG
ncRNAs in plasma EVs of AD patients and their discriminatory power as biomarkers$2,297,526
RF1 · FY2022 · AG · contact PI
The interplay between Tau and ncRNAs â genomic and epigenomic clues to early AD pathogenesis$706,518
R01 · FY2022 · AG
APOE Orchestrated Molecular Signatures in Aging Brain and AD-the Contribution of APOE2$635,903
R01 · FY2022 · AG · contact PI
APOE Orchestrated Molecular Signatures in Aging Brain and AD-the Contribution of APOE2$632,773
R01 · FY2021 · AG · contact PI
APOE Orchestrated Molecular Signatures in Aging Brain and AD-the Contribution of APOE2$624,948
R01 · FY2020 · AG · contact PI
APOE Orchestrated Molecular Signatures in Aging Brain and AD-the Contribution of APOE2$674,908
R01 · FY2019 · AG · contact PI
APOE Orchestrated Molecular Signatures in Aging Brain and AD-the Contribution of APOE2$634,993
R01 · FY2018 · AG · contact PI
Epigenetic and phenotypic effects of arsenic: impacts on cognition and AD$499,887
R01 · FY2018 · ES · contact PI
Age dependent APOE isoform specific effect on immune receptor mediated$344,102
RF1 · FY2018 · AG · contact PI
Age dependent APOE isoform specific effect on immune receptor mediated phagocytosis in brain$1,934,467
RF1 · FY2017 · AG · contact PI
Epigenetic and phenotypic effects of arsenic: impacts on cognition and AD$510,051
R01 · FY2017 · ES · contact PI
APOE orchestrated ''molecular signatures'' in aging brain and AD - the contribution of APOE2$440,615
R56 · FY2017 · AG · contact PI
Aging, Alzheimer's Disease & Epigenetics - Opportunities for Therapeutic Interventions International Conference - October 2017, Varna, BULGARIA$45,000
R13 · FY2017 · AG · contact PI
Epigenetic and phenotypic effects of arsenic: impacts on cognition and AD$519,919
R01 · FY2016 · ES · contact PI
Genome wide analysis of LXR binding - metabolic and epigenetic regulation in AD$517,554
R01 · FY2016 · AG · contact PI
Genome Wide Analysis LXR Binding-Metabolic and Epigenetic Regulation in AD$42,554
R01 · FY2016 · AG · contact PI
Epigenetic and phenotypic effects of arsenic: impacts on cognition and AD$529,500
R01 · FY2015 · ES · contact PI
Genome wide analysis of LXR binding - metabolic and epigenetic regulation in AD$460,750
R01 · FY2015 · AG · contact PI
Epigenetic and phenotypic effects of arsenic: impacts on cognition and AD$506,600
R01 · FY2014 · ES · contact PI
Genome wide analysis of LXR binding - metabolic and epigenetic regulation in AD$475,000
R01 · FY2014 · AG · contact PI
Genome wide analysis of LXR binding - metabolic and epigenetic regulation in AD$448,875
R01 · FY2013 · AG · contact PI
Epigenomic impact of diet and toxicant exposure in Alzheimers disease etiology$233,378
R21 · FY2013 · ES · contact PI
Genome wide analysis of LXR binding - metabolic and epigenetic regulation in AD$475,000
R01 · FY2012 · AG · contact PI
Epigenomic impact of diet and toxicant exposure in Alzheimers disease etiology$234,246
R21 · FY2012 · ES · contact PI
Screening for LXR agonists-inhibitors of brain amyloidosis and inflammation$128,775
R21 · FY2009 · AG · contact PI
Screening for LXR agonists-inhibitors of brain amyloidosis and inflammation$224,241
R21 · FY2008 · AG · contact PI
ABCA1 knock-in mouse model to study molecular pathology of Alzheimer's Disease$61,524
R03 · FY2007 · AG · contact PI
ABCA1 knock-in mouse model to study molecular pathology of Alzheimer's Disease$63,419
R03 · FY2006 · AG · contact PI
Therapeutic potential-LXR ligands in Alzheimer's Disease$57,137
R03 · FY2005 · AG
Therapeutic potential-LXR ligands in Alzheimer's Disease$57,246
R03 · FY2004 · AG